CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment
CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issuing a positive opinion. This recommendation is for the approval of sugemalimab, combined with chemotherapy, as a first-line treatment for metastatic non-small cell lung […]